



## Corrections to: Treatment of migraine: a review of disease burden and an update on the therapeutic landscape for pharmacists

Nishil Patel<sup>1</sup> · Rebecca Barnhart<sup>2</sup> · Paul Konkol<sup>3</sup> · Josephine Varda<sup>4</sup> · Rob Nelson<sup>1</sup> · Tim Smith<sup>5</sup>

Published online: 6 January 2021  
© The Author(s) 2021

**Correction to: Drugs & Therapy Perspectives (2020)**  
<https://doi.org/10.1007/s40267-020-00801-2>

“100 mg as IV infusion q3mo (may ↑ to 300 mg)”  
The original article has been corrected.

An Online First version of this article was made available online at <https://link.springer.com/article/10.1007/s40267-020-00801-2> on 5 December 2020. An error was subsequently identified in the article, and the following correction should be noted.

**Page 4, Table 2, 'Inhibitors of the CGRP pathway' section, 'Eptinezumab' row:** The cell entry in the 'Recommended dosage' column, which previously read:

“100 mg as IV infusion q1mo (may ↑ to 300 mg)”

should read:

---

The original article can be found online at <https://doi.org/10.1007/s40267-020-00801-2>.

✉ Nishil Patel  
npatel05@amgen.com

<sup>1</sup> Amgen Inc., US Medical Affairs, Thousand Oaks, CA, USA

<sup>2</sup> Ambulatory Care Pharmacy Services, UC Health University of Colorado Hospital, Aurora, CO, USA

<sup>3</sup> Pharmacy Specialty Services, SSM Health Pharmacy, Madison, WI, USA

<sup>4</sup> Department of Pharmacy, Diamond Headache Unit at AMITA Health Saint Joseph Hospital Chicago, Chicago, IL, USA

<sup>5</sup> StudyMetrix Research, LLC, Saint Peters, MO, USA